National projects managed by Innovation Acta
INNOVA
Progetto – PNC- E3-2022-23683266 – DIAGNOSTICA AVANZATA (HLS-DA), finanziato dal Ministero della Salute nell’ambito del Piano Nazionale Complementare Ecosistema Innovativo della Salute.
Starting Date: 2 January 2023
Project number: PNC- E3-2022-23683266
MoH Funding: € 40,000,000
Currently ongoing grants Horizon Europe and Horizon 2020
IHI/IMI
LIVERAIM
101132901-HORIZON-JU-IHI-2022-03-single-stage
A biomarker-based platform for early diagnosis of chronic liver disease to enable personalised therapy
Starting Date: 1 March 2024
Grant Agreement: 101132901
Project Cost: € 24,789,953.89
EC Funding: € 13,854,592.75
GUIDE.MRD
Project 101080562101112066- HORIZON-JU-IHI-2022-01-03
GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD
Starting Date: 1 May 2023
Grant Agreement: 101112066
Project Cost: € 34.452.565
EC Funding: € 17.660.955
NECESSITY
IMI Grant
New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifying patients
Starting Date: 1 January 2019
Grant Agreement: 806975
Project Cost: € 15.485.964,84
EU Contribution: € 8.200.000,00
RIA-MISSION
THRIVE
Project: 101136622 -HORIZON-MISS-2023-CANCER-01
Tumour-host interactions in liver cancer of Childhood and adults
Starting date: 1 December 2023
Grant Agreement: 101136622
Project cost: € 10.396.703
EC funding: € 10.396.703
RIA-HEALTH
IMMUTOL
Project 101080562- HORIZON-HLTH-2022-DISEASE-06-two-stage
Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases
Starting Date: 1 May 2023
Grant Agreement: 101080562
Project Cost: € 5.999.340
PROTO
Project 101095635- HORIZON-HLTH-2022-STAYHLTH-02-01
Advanced PeRsOnalized Therapies for Osteoarthritis –Tackling inflammation to improve patient outcomes
Starting Date: 1 January 2023
Grant Agreement: 101095635
Project Cost: € 7.447.875
geneTIGA
Project 101057438 - HORIZON-HLTH-2021-TOOL-06
Gene-edited T cells combating IgA Nephropathy
Starting Date: 1 July 2022
Grant Agreement: 101057438
Project Cost: € 5.736.859
ReSHAPE
RIA BHC 09-2018
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches - from Advanced Technology Developments to First-in-Human Trials
Starting Date: 1 January 2019
Grant Agreement: 825392
Budget: € 13.137.396,25
LIVERSCREEN
RIA BHC 30-2019
Screening for liver fibrosis - population-based study across European countries
Starting Date: 1 January 2020
Grant Agreement: 847989
HDM-FUN
RIA BHC14-2019
Host directed medicine in invasive fungal infection
Starting Date: 1 January 2020
Grant Agreement: 847507
EIC Pathfinder
B-SPECIFIC
Project 101115159 - HORIZON-EIC-2022-PATHFINDERCHALLENGES-01
B-cell related gene and protein markers with prognostic and therapeutic value for CVD
Starting Date: 1 October 2023
Grant Agreement: 101115159
Project Cost: € 4.006.599,85
T-FITNESS
Project 101070740 - HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Fine-Tuning T Cell Networks of Exhaustion by Synthetic Sensors
Starting Date: 1 September 2022
Grant Agreement: 101070740
Project Cost: € 3.789.472
TwistedNano
Project 101046424 - HORIZON-EIC-2021-PATHFINDEROPEN-01
Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip
Starting Date: 1 April 2022
Grant Agreement: 101046424
Project Cost: € 3.197.925
MSCA DN and ITN
Glyco-N
Project: 101119499 - HORIZON-MSCA-2022-DN-01
GLYCOprotein N-glycosylation from non-life to eukaryotes: a Doctoral Network to expand the knowledge on a ubiquitous posttranslational modification of proteins
Starting Date: 1 February 2024
Grant Agreement: 101119499
Project Cost: € 2.677.118,4
EC funding: € 2.677.118,4
ECO2WINE
Project: HORIZON-MSCA-2022-DN-01-01 (topic)
Natural microbial interactions in winemaking-associated ecosystems as a tool to foster wine innovation
Starting Date: 1 December 2023
Grant Agreement: 101119480
Project Cost: € 2.440.396,80
EC funding: € 2.440.396,80
TOPGUT
Project MSCA-DN
Training for Organoids modelling Physiology and Pathology in the human gastrointestinal tract
Starting Date: 1 November 2023
Grant Agreement: 101119911
Budget: € 2.718.489,60
EXTRA
Project MSCA-DN
Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation
Starting Date: 1 September 2023
Grant Agreement: 101119855
Budget: € 2.613.103,20
TREAD
Project: 101072699- HORIZON-MSCA-2021-DN-01
daTa and pRocesses in sEismic hAzarD
Starting Date: 1 January 2023
Grant Agreement: 101072699
Budget: € 2.664.388,80
EC funding: € 2.664.388,80
TOLERATE
MSCA-DN
An integrated approach to restore tolerance in autoimmune disease
Starting Date: 1 October 2022
Grant Agreement: 101072729
Budget: € 2.109.650,40
INsTRuCT
MSCA-ITN (ETN)
INnovative Training in Myeloid Regulatory Cell Therapy
Starting Date: 1 January 2020
Grant Agreement: 860003
Budget: € 4.021.026,84
EDUC8
MSCA-ITN (ETN)
Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity
Starting Date: 1 April 2020
Grant Agreement: 859974
Closed H2020 grants
RESTORE
CSA - Large Scale Research Initiative
RESTORE Health by Advanced Therapies (Advanced Therapy Medicinal Products and Biologized Medical Devices) – ALL for Advanced Therapies – with Passion – For Patients’
Starting Date: 1 March 2019
Grant Agreement: 820292
Project Cost: € 1.000.000
EU Contribution: € 1.000.000
HIPGEN
RIA - Research and Innovation action
Placenta-expanded adherent stromal cells (plx-pad) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty - HIPGEN, a multicenter phase III trial
Starting Date: 1 January 2018
Grant Agreement: 779293
PACE
RIA - Research and Innovation action
A multicenter phase III study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies
Starting Date: 1 January 2017
Grant Agreement: 733006
LIVERHOPE
RIA - Research and Innovation action
Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis
Starting Date: 1 January 2017
Grant Agreement: 731875
INTEGRATA
MSCA-ITN (ETN)
Integrating chemical and biological approaches to target NAD production and signaling in cancer
Starting Date: 1 November 2018
Grant Agreement: 813284
Budget: € 3.738.573,00